Speakers 2009
-
(chairman)
Presentation
-
ALBERTI Alfredo
Italy
-
What are the co-morbidities influencing the management of patients and the response to therapy ?
-
Management of non naive patients with hepatitis C (chairman)
Presentation
-
ALTER Harvey
USA
-
1989 -2009 : HCV twenty years after From B to non B to C : the historical evolution of hepatitises viruses
Presentation
-
ANTAKI Nabil
Syria
-
Genotype 4 : how to treat ?
Presentation
-
-
New drugs : Enzyme inhibitors
Presentation
-
-
Non invasive fibrosis markers and/or liver biopsy ?
Presentation
-
BELHADJ BRIK Najet
Tunisia
-
French Luncheon : comment prendre en charge les patients atteints d’hépatite B avec les médicaments disponibles dans mon pays
Presentation
-
-
French Luncheon : comment prendre en charge les patients atteints d’hépatite B avec les médicaments disponibles dans mon pays
Presentation
-
BERKANE Saadi
Algeria
-
French Luncheon : comment prendre en charge les patients atteints d’hépatite C avec les médicaments disponibles dans mon pays.
Presentation
-
-
(chairman)
-
Hepatitis B: predictors and endpoints revisited? (chairman)
Presentation
-
-
(chairman)
Presentation
-
BRUIX Jordi
Spain
-
New drugs for hepatocellular carcinoma
Presentation
-
BRUNETTO Maurizia
Italy
-
New endpoints. Back to the future with Australia Antigen ?
Presentation
-
-
End stage HBV-related liver disease: what’s left to do? (chairman)
-
Screening and diagnosis of hepatocellular carcinoma
Presentation
-
-
Optimal therapy in genotype 2 and 3 patients
Presentation
-
-
French Luncheon : comment prendre en charge les patients atteints d’hépatite C avec les médicaments disponibles dans mon pays. (chairman)
Presentation
-
DI BISCEGLIE Adrian
USA
-
Hepatocellular carcinoma (chairman)
Presentation
-
-
End stage HBV-related liver disease: what’s left to do?
Presentation
-
DUSHEIKO Geoffrey
UK
-
HBeAg-positive chronic hepatitis B (chairman)
Presentation
-
ESSAID EL FEYDI Abdellah
Maroc
-
French Luncheon : comment prendre en charge les patients atteints d’hépatite C avec les médicaments disponibles dans mon pays.
Presentation
-
-
Hepatocellular carcinoma (chairman)
Presentation
-
-
Optimizing therapy in real life illustrated with clinical cases (chairman)
Presentation
-
-
Optimizing therapy in real life illustrated with clinical cases (chairman)
Presentation
-
HADZIYANNIS Stephanos
Greece
-
HBeAg negative chronic hepatitis B (chairman)
Presentation
-
HEATHCOTE Jenny
Canada
-
Retreatment : who and how ?
Presentation
-
HORBAN Andrzej
Poland
-
Clinical Management of hepatitis C in an environment with limited access to treatment
Presentation
-
HOUGHTON Michael
USA
-
The HCV discovery
Presentation
-
IVASHKIN Vladimir
Russia
-
How to manage patients with hepatitis B with limited access to care ?
Presentation
-
-
How to manage patients with hepatitis B with limited access to care ?
Presentation
-
JONAS Maureen
USA
-
Hepatitis B and pregnancy : an underestimated issue
Presentation
-
KAMAL Sanaa
Egypt
-
Optimal therapy in genotype 4 patients
-
Genotype 4 : how to treat ?
Presentation
-
-
Why do I treat my patients with nucleos(t)ide analogs ?
-
How to optimize the management of my HBeAg negative patient?
Presentation
-
-
Why do I treat my patients with pegylated interferon ?
Presentation
-
LAVANCHY Daniel
Switzerland
-
The burden of hepatitis C in Europe. Epidemiology, actions to increase awareness and access to care (chairman)
-
The global burden of hepatitis C
Presentation
-
-
Why do I treat my patients with nucleos(t)ide analogs ?
Presentation
-
LIAW Yun-Fan
Taiwan
-
Natural history of HBV and long-term outcome under treatment
Presentation
-
-
Management of non naive patients with hepatitis C
Presentation
-
MANNS Michael
Germany
-
(chairman)
Presentation
-
-
Introduction : Viral Hepatitis in 2009
-
State of the Art Lecture
-
EASL clinical pratice guidelines : management of chronic hepatitis B
-
Conclusion and perspectives
Presentation
-
MATHURIN Philippe
France
-
The burden of hepatitis C in Europe. Epidemiology, actions to increase awareness and access to care
Presentation
-
MOUCARI Rami
United Arab Emirates
-
Hepatitis B: predictors and endpoints revisited?
Presentation
-
MUEHLBERGER Nikolai
Austria
-
The burden of hepatitis C in Europe. Epidemiology, actions to increase awareness and access to care
Presentation
-
-
(chairman)
Presentation
-
PAWLOTSKY Jean-Michel
France
-
How to use the virological tools for the optimal follow up of chronic hepatitis C
Presentation
-
PERRILLO Robert
USA
-
Why do I treat my patients with pegylated interferon ?
-
How to manage patients with hepatitis B with limited access to care ? (chairman)
Presentation
-
PETERS Marion
USA
-
Clinical case
Presentation
-
-
Management of HIV-HCV co-infected patients (chairman)
-
HBeAg-positive chronic hepatitis B (chairman)
Presentation
-
-
Hepatitis D: the come back ?
Presentation
-
ROCKSTROH Juergen
Germany
-
Management of HIV-HCV co-infected patients
Presentation
-
-
(chairman)
Presentation
-
SARRAZIN Christoph
Germany
-
Management of non naive patients with hepatitis C
-
French Luncheon : comment prendre en charge les patients atteints d’hépatite C avec les médicaments disponibles dans mon pays.
Presentation
-
-
Clinical Management of hepatitis C in an environment with limited access to treatment (chairman)
-
Clinical case
Presentation
-
SEEFF Leonard
USA
-
The history of the "natural history" of hepatitis C
Presentation
-
-
What future for ribavirin ?
Presentation
-
-
French Luncheon : comment prendre en charge les patients atteints d’hépatite B avec les médicaments disponibles dans mon pays (chairman)
Presentation
-
WRIGHT Teresa
USA
-
(chairman)
Presentation
-
YURDAYDIN Cihan
Turkey
-
(chairman)
Presentation
-
-
HBeAg negative chronic hepatitis B (chairman)
-
How to optimize the management of my HBeAg negative patient? (chairman)
Presentation
-
ZEUZEM Stefan
Germany
-
Optimizing therapy in real life illustrated with clinical cases Optimal therapy in genotype 1 patients
Presentation
-
ZOULIM Fabien
France
-
How to prevent, diagnose and overcome resistance under nucleos(t)ide analogs ?
Presentation
-
